RxDoctor Payments Data

Dawn Brink Cymerman, MD

Family Medicine · Cazenoviz, NYNPI 1689604357

Payments from drug & device makers

$1,479in general payments, 2019–2025

Across 67 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$293
  • Baxter Healthcare$187
  • GSK$157
  • Novo Nordisk$109
  • Pfizer$91
  • Lilly USA, LLC$80
  • plus $562 from 17 others

What the payments were for

  • Food & beverage$1,29287%
  • Other$18713%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,479 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$66,127
Medicare patients
214
Services billed
1,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$96,960
EliquisApixaban104$87,400
JardianceEmpagliflozin32$44,726
TrulicityDulaglutide25$30,793
MounjaroTirzepatide23$24,159
WegovySemaglutide15$22,920
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$16,414
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,498
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$8,876
Breo ElliptaFluticasone/Vilanterol12$6,152
Spiriva RespimatTiotropium Bromide11$5,515
ArexvyRsvpref3 Antigen/As01e/Pf13$4,154
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$3,366
Climara ProEstradiol/Levonorgestrel13$2,965
Insulin Lispro Kwikpen U-100Insulin Lispro17$2,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$109$119,88097 claims
PfizerEliquis$91$87,400104 claims
Lilly USA, LLCTrulicity, Mounjaro$80$54,95148 claims
Boehringer IngelheimJardiance, Spiriva Respimat$48$50,24143 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy$157$22,80345 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.

Other family medicine in Cazenoviz

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →